See more : System Support Inc. (4396.T) Income Statement Analysis – Financial Results
Complete financial analysis of Abiomed, Inc. (ABMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abiomed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Regeneron Pharmaceuticals, Inc. (REGN) Income Statement Analysis – Financial Results
- Diversified Healthcare Trust (DHCNL) Income Statement Analysis – Financial Results
- Huafu Fashion Co., Ltd. (002042.SZ) Income Statement Analysis – Financial Results
- Red White & Bloom Brands Inc. (RWB.CN) Income Statement Analysis – Financial Results
- India Motor Parts & Accessories Limited (IMPAL.NS) Income Statement Analysis – Financial Results
Abiomed, Inc. (ABMD)
About Abiomed, Inc.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.03B | 847.52M | 840.88M | 769.43M | 593.75M | 445.30M | 329.54M | 230.31M | 183.64M | 158.12M | 126.38M | 101.15M | 85.71M | 73.21M | 58.94M | 50.65M | 43.67M | 38.22M | 25.74M | 23.31M | 26.86M | 24.90M | 22.52M | 22.09M | 22.45M | 16.46M | 12.84M | 9.20M | 6.70M | 3.40M | 2.70M | 2.00M | 3.00M | 2.90M | 4.20M | 4.70M |
| Cost of Revenue | 188.16M | 161.91M | 151.31M | 129.57M | 98.58M | 70.63M | 50.42M | 39.95M | 37.32M | 31.60M | 24.51M | 21.98M | 22.53M | 20.44M | 15.07M | 12.01M | 11.69M | 9.37M | 7.59M | 7.50M | 7.92M | 7.38M | 5.88M | 6.77M | 6.50M | 5.36M | 3.92M | 2.90M | 1.90M | 3.00M | 2.00M | 1.30M | 1.00M | 1.10M | 200.00K | 3.70M |
| Gross Profit | 843.60M | 685.62M | 689.58M | 639.87M | 495.17M | 374.68M | 279.12M | 190.37M | 146.32M | 126.53M | 101.87M | 79.17M | 63.18M | 52.77M | 43.88M | 38.64M | 31.99M | 28.85M | 18.15M | 15.81M | 18.94M | 17.52M | 16.64M | 15.32M | 15.94M | 11.10M | 8.92M | 6.30M | 4.80M | 400.00K | 700.00K | 700.00K | 2.00M | 1.80M | 4.00M | 1.00M |
| Gross Profit Ratio | 81.76% | 80.90% | 82.01% | 83.16% | 83.40% | 84.14% | 84.70% | 82.66% | 79.68% | 80.02% | 80.61% | 78.27% | 73.72% | 72.08% | 74.44% | 76.28% | 73.24% | 75.49% | 70.51% | 67.82% | 70.53% | 70.38% | 73.88% | 69.34% | 71.03% | 67.44% | 69.47% | 68.48% | 71.64% | 11.76% | 25.93% | 35.00% | 66.67% | 62.07% | 95.24% | 21.28% |
| Research & Development | 163.40M | 121.88M | 98.76M | 93.50M | 75.30M | 66.39M | 49.76M | 35.97M | 30.71M | 25.65M | 27.16M | 26.68M | 25.95M | 25.33M | 24.92M | 22.29M | 30.05M | 13.50M | 14.30M | 20.55M | 27.37M | 22.67M | 15.63M | 13.45M | 9.09M | 3.83M | 3.22M | 2.50M | 2.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 321.55M | 262.73M | 218.15M | 164.26M | 125.73M | 107.25M | 84.23M | 71.71M | 62.29M | 60.84M | 55.36M | 52.66M | 42.45M | 30.92M | 18.61M | 14.10M | 14.75M | 16.20M | 12.41M | 12.56M | 9.77M | 9.05M | 7.07M | 5.74M | 4.30M | 4.40M | 4.60M | 6.40M | 8.80M | 5.20M | 4.80M | 5.10M | 900.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 423.49M | 334.18M | 341.60M | 321.55M | 262.73M | 218.15M | 164.26M | 125.73M | 107.25M | 84.23M | 71.71M | 62.29M | 60.84M | 55.36M | 52.66M | 42.45M | 30.92M | 18.61M | 14.10M | 14.75M | 16.20M | 12.41M | 12.56M | 9.77M | 9.05M | 7.07M | 5.74M | 4.30M | 4.40M | 4.60M | 6.40M | 8.80M | 5.20M | 4.80M | 5.10M | 900.00K |
| Other Expenses | 0.00 | 51.95M | -4.56M | 30.38M | -388.00K | -349.00K | 339.00K | -97.00K | 49.00K | 326.00K | 1.48M | 1.40M | 1.47M | 1.61M | 2.79M | 1.61M | 1.31M | 13.23M | 13.63M | 20.37M | 0.00 | 0.00 | 0.00 | 0.00 | -1.21M | 0.00 | 0.00 | 400.00K | 300.00K | 300.00K | 600.00K | 300.00K | 200.00K | 200.00K | 200.00K | 200.00K |
| Operating Expenses | 586.89M | 456.06M | 440.36M | 415.05M | 338.03M | 284.54M | 214.02M | 161.70M | 137.96M | 109.99M | 100.35M | 90.36M | 88.26M | 82.29M | 80.36M | 66.35M | 62.28M | 32.10M | 28.40M | 35.30M | 43.56M | 35.08M | 28.20M | 23.22M | 16.94M | 10.90M | 8.96M | 7.20M | 7.10M | 4.90M | 7.00M | 9.10M | 5.40M | 5.00M | 5.30M | 1.10M |
| Cost & Expenses | 775.05M | 617.97M | 591.66M | 544.62M | 436.61M | 355.17M | 264.44M | 201.65M | 175.28M | 141.58M | 124.86M | 112.34M | 110.79M | 102.73M | 95.43M | 78.36M | 73.96M | 41.47M | 35.99M | 42.80M | 51.48M | 42.46M | 34.08M | 29.99M | 23.44M | 16.26M | 12.88M | 10.10M | 9.00M | 7.90M | 9.00M | 10.40M | 6.40M | 6.10M | 5.50M | 4.80M |
| Interest Income | 49.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.09M | 17.38M | 8.26M | 14.12M | 11.01M | 6.20M | 3.28M | 2.77M | 2.51M | 2.72M | 4.34M | 3.95M | 4.90M | 5.02M | 6.12M | 3.92M | 2.74M | 1.24M | 1.39M | 1.70M | 1.77M | 2.97M | 1.69M | 1.39M | 876.94K | 429.61K | 349.76K | 400.00K | 300.00K | 300.00K | 600.00K | 300.00K | 200.00K | 200.00K | 200.00K | 200.00K |
| EBITDA | 400.78M | 246.94M | 257.48M | 230.77M | 164.45M | 94.79M | 67.99M | 31.24M | 10.75M | 19.27M | 4.83M | -7.56M | -26.90M | -23.18M | -25.24M | -24.10M | -27.55M | -2.12M | -9.04M | -17.96M | -22.85M | -14.59M | -9.88M | -6.52M | -118.18K | 629.77K | 313.01K | -900.00K | -2.40M | -4.80M | -6.90M | -9.80M | -4.70M | -3.90M | -1.80M | -100.00K |
| EBITDA Ratio | 38.84% | 29.14% | 30.62% | 29.99% | 27.70% | 21.29% | 20.63% | 13.56% | 5.86% | 12.19% | 3.82% | -7.47% | -31.38% | -31.66% | -42.82% | -47.58% | -63.09% | -5.56% | -35.11% | -77.05% | -85.08% | -58.62% | -43.86% | -29.51% | -0.53% | 3.83% | 2.44% | -9.78% | -35.82% | -141.18% | -255.56% | -490.00% | -156.67% | -134.48% | -42.86% | -2.13% |
| Operating Income | 372.69M | 229.56M | 249.22M | 224.81M | 157.14M | 90.14M | 65.10M | 28.67M | 8.36M | 16.54M | 1.52M | -11.19M | -25.08M | -29.52M | -36.49M | -28.51M | -30.29M | -3.25M | -10.25M | -19.49M | -24.62M | -17.56M | -11.56M | -7.90M | -995.12K | 200.16K | -36.75K | -900.00K | -2.30M | -4.50M | -6.30M | -8.40M | -3.40M | -3.20M | -1.30M | -100.00K |
| Operating Income Ratio | 36.12% | 27.09% | 29.64% | 29.22% | 26.47% | 20.24% | 19.76% | 12.45% | 4.55% | 10.46% | 1.20% | -11.06% | -29.26% | -40.32% | -61.90% | -56.29% | -69.36% | -8.51% | -39.83% | -83.62% | -91.67% | -70.54% | -51.34% | -35.78% | -4.43% | 1.22% | -0.29% | -9.78% | -34.33% | -132.35% | -233.33% | -420.00% | -113.33% | -110.34% | -30.95% | -2.13% |
| Total Other Income/Expenses | -182.13M | 58.66M | 7.61M | 38.55M | 3.30M | 1.21M | 734.00K | 99.00K | 167.00K | 319.00K | 1.02M | 322.00K | 6.72M | -1.33M | -3.92M | 1.11M | 1.20M | 911.00K | 806.00K | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 400.00K | 600.00K | 1.20M | 1.70M | 1.50M | 900.00K | 700.00K | 200.00K |
| Income Before Tax | 190.56M | 288.22M | 256.83M | 263.36M | 160.44M | 91.34M | 65.84M | 28.77M | 8.53M | 16.86M | 2.54M | -10.86M | -18.35M | -30.85M | -40.40M | -27.41M | -29.09M | -2.34M | -9.45M | -18.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | -1.90M | -3.90M | -5.10M | -6.70M | -1.90M | -2.30M | -600.00K | 100.00K |
| Income Before Tax Ratio | 18.47% | 34.01% | 30.54% | 34.23% | 27.02% | 20.51% | 19.98% | 12.49% | 4.64% | 10.66% | 2.01% | -10.74% | -21.41% | -42.13% | -68.55% | -54.11% | -66.62% | -6.13% | -36.70% | -77.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -28.36% | -114.71% | -188.89% | -335.00% | -63.33% | -79.31% | -14.29% | 2.13% |
| Income Tax Expense | 54.06M | 62.70M | 53.82M | 4.34M | 48.27M | 39.23M | 27.69M | -84.92M | 1.18M | 1.85M | 1.05M | 892.00K | 671.00K | 752.00K | 527.00K | 475.00K | 356.00K | 110.00K | 172.00K | 173.00K | -2.95M | -6.16M | -1.11M | -1.19M | 1.51M | -535.10K | -527.87K | -500.00K | 400.00K | 600.00K | 1.20M | 1.70M | 1.50M | 900.00K | 700.00K | 200.00K |
| Net Income | 136.51M | 225.53M | 203.01M | 259.02M | 112.17M | 52.12M | 38.15M | 113.69M | 7.35M | 15.01M | 1.50M | -11.76M | -19.02M | -31.60M | -40.93M | -27.88M | -29.45M | -2.34M | -9.45M | -18.17M | -21.68M | -11.40M | -10.45M | -6.71M | -2.51M | 735.26K | 491.12K | -400.00K | -2.00M | -3.90M | -5.10M | -6.60M | -1.90M | -2.20M | -600.00K | 100.00K |
| Net Income Ratio | 13.23% | 26.61% | 24.14% | 33.66% | 18.89% | 11.70% | 11.58% | 49.36% | 4.00% | 9.50% | 1.18% | -11.62% | -22.19% | -43.16% | -69.44% | -55.05% | -67.44% | -6.13% | -36.70% | -77.95% | -80.71% | -45.79% | -46.43% | -30.39% | -11.17% | 4.47% | 3.82% | -4.35% | -29.85% | -114.71% | -188.89% | -330.00% | -63.33% | -75.86% | -14.29% | 2.13% |
| EPS | 3.00 | 5.00 | 4.49 | 5.77 | 2.54 | 1.21 | 0.90 | 2.80 | 0.19 | 0.38 | 0.04 | -0.32 | -0.52 | -0.91 | -1.26 | -1.03 | -1.15 | -0.11 | -0.45 | -0.87 | -1.04 | -0.55 | -0.59 | -0.39 | -0.16 | 0.05 | 0.04 | -0.03 | -0.16 | -0.30 | -0.40 | -0.54 | -0.18 | -0.24 | -0.07 | 0.01 |
| EPS Diluted | 2.98 | 4.94 | 4.43 | 5.61 | 2.45 | 1.17 | 0.85 | 2.65 | 0.18 | 0.37 | 0.04 | -0.32 | -0.52 | -0.91 | -1.26 | -1.03 | -1.15 | -0.11 | -0.45 | -0.87 | -1.04 | -0.55 | -0.59 | -0.39 | -0.16 | 0.05 | 0.04 | -0.03 | -0.16 | -0.30 | -0.40 | -0.54 | -0.18 | -0.24 | -0.07 | 0.01 |
| Weighted Avg Shares Out | 45.45M | 45.14M | 45.18M | 44.91M | 44.15M | 43.24M | 42.20M | 40.63M | 39.33M | 39.11M | 38.37M | 37.17M | 36.68M | 34.88M | 32.47M | 27.12M | 25.65M | 21.84M | 21.15M | 20.99M | 20.87M | 20.58M | 17.58M | 17.24M | 16.15M | 14.32M | 13.99M | 13.02M | 12.50M | 13.00M | 12.75M | 12.22M | 10.56M | 9.17M | 8.57M | 6.90M |
| Weighted Avg Shares Out (Dil) | 45.88M | 45.67M | 45.82M | 46.15M | 45.85M | 44.66M | 44.90M | 42.86M | 41.61M | 41.05M | 40.17M | 37.17M | 36.68M | 34.88M | 32.47M | 27.12M | 25.65M | 21.84M | 21.15M | 20.99M | 20.87M | 20.58M | 17.58M | 17.24M | 16.15M | 14.32M | 13.99M | 13.02M | 12.50M | 13.00M | 12.75M | 12.22M | 10.56M | 9.17M | 8.57M | 6.90M |
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
DANVERS, Mass.--(BUSINESS WIRE)--Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
Why Shares of Abiomed Rose 18.4% in July
The company's stock rose steadily throughout the month.
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript
Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer...
Abiomed: Small Premium For Access To ~11% Normalized ROIC
Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
DANVERS, Mass.--(BUSINESS WIRE)--ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%,...
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces first quarter record revenue of $277 million, up 10% year over year, up 12% in constant currency.
2 Medical Device Stocks With Extremely High GF Scores
The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperform. Those stocks with higher GF Scores generally produce...
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m....
Source: https://incomestatements.info
Category: Stock Reports